InterCure reported NIS 130 million in revenue and NIS 12 million in positive operating cash flow for the first half of 2025, marking its eleventh consecutive half of positive Adjusted EBITDA. The company remains resilient amidst ongoing recovery in Israel. InterCure is optimistic about U.S. regulatory changes and its recent agreement to acquire ISHI, positioning it well in the evolving cannabis market landscape. The company is closely monitoring potential rescheduling of cannabis in the U.S. for further opportunities.

In the first half of 2025, InterCure saw a 15% increase in revenue to NIS 130 million compared to the second half of 2024. The company achieved positive Adjusted EBITDA for the eleventh consecutive half year, with NIS 12.6 million representing 10% of revenue. InterCure also reported positive cash flow from operations of NIS 12 million and had NIS 54 million in cash on hand as of June 30, 2025.

Operational highlights include the resumption of production at the Nir Oz facility, launching over 40 new products, and receiving NIS 81 million in compensation advances for war-related damages. The acquisition of Botanico Ltd. (ISHI) is expected to enhance InterCure’s access to premium U.S. genetics and international market opportunities. The exclusive supply agreement under the ISHI acquisition is projected to contribute tens of millions of shekels to the company’s revenues.

InterCure, known as Canndoc, is Israel’s largest licensed cannabis producer and a key player in the global cannabis market. The company leverages a high-margin vertically integrated model and GMP-certified products to lead the industry outside North America. For more financial information, refer to the Company’s annual reports and filings available on the SEC’s EDGAR profile.

Read more at GlobeNewswire: InterCure Reports First Half 2025 Results with NIS 130